The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled Trial
Open accessAbstract
CONTEXT: Despite decades of accumulated observational evidence, the balance of risks and benefits for hormone use in healthy postmenopausal women remains uncertain. OBJECTIVE: To assess the major health benefits and risks of the most commonly used combined hormone preparation in the United States. DESIGN: Estrogen plus progestin component of the Women's Health Initiative, a randomized controlled primary prevention trial (planned duration, 8.5 years) in which 16608 postmenopausal women aged 50-79 years with an intact uterus at baseline were recruited by 40 US clinical centers in 1993-1998. INTERVENTIONS: Participants received conjugated equine estrogens, 0.625 mg/d, plus medroxyprogesterone acetate, 2.5 mg/d, in 1 tablet (n = 8506) or placebo (n = 8102). MAIN OUTCOMES MEASURES: The primary outcome was coronary heart disease (CHD) (nonfatal myocardial infarction and CHD death), with invasive breast cancer as the primary adverse outcome. A global index summarizing the balance of risks and benefits included the 2 primary outcomes plus stroke, pulmonary embolism (PE), endometrial cancer, colorectal cancer, hip fracture, and death due to other causes. RESULTS: On May 31, 2002, after a mean of 5.2 years of follow-up, the data and safety monitoring board recommended stopping the trial of estrogen plus progestin vs placebo because the test statistic for invasive breast cancer exceeded the stopping boundary for this adverse effect and the global index statistic supported risks exceeding benefits. This report includes data on the major clinical outcomes through April 30, 2002. Estimated hazard ratios (HRs) (nominal 95% confidence intervals [CIs]) were as follows: CHD, 1.29 (1.02-1.63) with 286 cases; breast cancer, 1.26 (1.00-1.59) with 290 cases; stroke, 1.41 (1.07-1.85) with 212 cases; PE, 2.13 (1.39-3.25) with 101 cases; colorectal cancer, 0.63 (0.43-0.92) with 112 cases; endometrial cancer, 0.83 (0.47-1.47) with 47 cases; hip fracture, 0.66 (0.45-0.98) with 106 cases; and death due to other causes, 0.92 (0.74-1.14) with 331 cases. Corresponding HRs (nominal 95% CIs) for composite outcomes were 1.22 (1.09-1.36) for total cardiovascular disease (arterial and venous disease), 1.03 (0.90-1.17) for total cancer, 0.76 (0.69-0.85) for combined fractures, 0.98 (0.82-1.18) for total mortality, and 1.15 (1.03-1.28) for the global index. Absolute excess risks per 10 000 person-years attributable to estrogen plus progestin were 7 more CHD events, 8 more strokes, 8 more PEs, and 8 more invasive breast cancers, while absolute risk reductions per 10 000 person-years were 6 fewer colorectal cancers and 5 fewer hip fractures. The absolute excess risk of events included in the global index was 19 per 10 000 person-years. CONCLUSIONS: Overall health risks exceeded benefits from use of combined estrogen plus progestin for an average 5.2-year follow-up among healthy postmenopausal US women. All-cause mortality was not affected during the trial. The risk-benefit profile found in this trial is not consistent with the requirements for a viable intervention for primary prevention of chronic diseases, and the results indicate that this regimen should not be initiated or continued for primary prevention of CHD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although hormone therapy is effective in treating hot flashes, its use is contraindicated for individuals initiating hormone therapy more than 10 years from menopause onset or older than 60 years, and with a history of breast cancer, uterine cancer, thromboembolic, or cardiovascular diseases.10,11,12”
From Self-Administered Hypnosis vs Sham Hypnosis for Hot Flashes (2025) · cites this paper as [10]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The WHI reported increased risks of myocardial infarction, stroke, invasive breast cancer, pulmonary emboli, and deep vein thrombosis during 5 years of treatment with conjugated equine estrogen and medroxyprogesterone acetate (Prempro®) [69].”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [69]
The cited source says what the claim attributes to it.
In the citing paper
“The Woman’s Health Initiative (WHI) found that 5 years of HT (Prempro®) reduced the risk of clinical vertebral fractures and hip fractures by 34 % and other osteoporotic fractures by 23 % [69].”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [69]
The cited source says what the claim attributes to it.
In the citing paper
“The Woman’s Health Initiative (WHI) found that 5 years of HT (Prempro®) reduced the risk of clinical vertebral fractures and hip fractures by 34 % and other osteoporotic fractures by 23 % [69].”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [69]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Yet all of about 90 HIV vaccines that succeeded in animals failed in humans.55”
From The Flaws and Human Harms of Animal Experimentation (2015) · cites this paper as [55]
Experimental — accuracy not yet measured
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“The increases were followed by equally pointed reductions within a few years, likely reflecting a depletion of prevalent cancers”
From Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. (2024) · cites this paper as [89]
Experimental — accuracy not yet measuredIn the citing paper
“Data from the Women’s Health Initiative (WHI) shows several risks of menopausal hormone therapy among healthy postmenopausal women, including an excess risk of coronary heart disease, stroke, and breast cancer (151).”
From From mitochondria to sarcopenia: role of 17β-estradiol and testosterone (2023) · cites this paper as [151]
In the citing paper
“The recent data of the Women's Health Initiative Study show that the combination of Premarin and Provera (Prempro) causes a 26% increase in the risk of breast cancer at 5.2 yr of follow-up”
In the citing paper
“the recent results of the Women's Health Initiative Study (8) clearly indicate that this compound is not recommended for longterm use in normal women where the stimulatory progestational component could well be predominant.”
In the citing paper
“The most effective treatment of hot flushes is estrogen replacement therapy, but the Women’s Health Initiative Study raised questions about the long-term safety of this treatment (Rossouw et al., 2002).”
From Modulation of body temperature and LH secretion by hypothalamic KNDy (kisspeptin, neurokinin B and dynorphin) neurons: A novel hypothesis on the mechanism of hot flushes (2013) · cites this paper as Rossouw et al., 2002
In the citing paper
“Estrogen replacement therapy and hormone replacement therapy appear to have a neutral effect on BP, as illustrated by the following observations from 2 large randomized trials.”
From Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association (2018) · cites this paper as [212]
In the citing paper
“The Women’s Health Initiative, a randomized placebo-controlled trial, assessed the effect of estrogen-progestin replacement on outcomes in postmenopausal women211 and found that at 5.2 years hormone replacement therapy produced only a small increase (1.5 mm Hg) in SBP compared with placebo.212”
From Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association (2018) · cites this paper as [212]
In the citing paper
“Estrogen has also been associated with increased risk of “unusual site” thromboses, as well as arterial thrombosis.”
From Estrogen and thrombosis: a bench to bedside review (2020) · cites this paper as [97]
In the citing paper
“That same year, data from the Women’s Health Initiative randomized clinical trial showed an increased risk of MI and cardiovascular death in women on MHT (HR 1.29, 95% CI, 1.02–1.63) [97].”
From Estrogen and thrombosis: a bench to bedside review (2020) · cites this paper as [97]
In the citing paper
“For example, the hypothesis that the effect of hormone replacement therapy (HRT) on coronary heart disease (CHD) might differ depending on the timing of its use (in relation to menopausal status) was not raised until after results from RCTs were published.47,48”
From Triangulation in aetiological epidemiology (2017) · cites this paper as [48]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hulley, S. (1998) · JAMA · doi:10.1001/jama.280.7.605 · Cited by 6,216
Gail, M. H., Brinton, L. A., Byar, D. P., Corle, D. K., Green, S. B., Schairer, C., & Mulvihill, J. J. (1989) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/81.24.1879 · Cited by 3,334
A Multiple Testing Procedure for Clinical Trials
O'Brien, P. C., & Fleming, T. R. (1979) · Biometrics · doi:10.2307/2530245 · Cited by 3,311
Design of the Women’s Health Initiative Clinical Trial and Observational Study
The Women’s Health Initiative Study Group (1998) · Controlled Clinical Trials · doi:10.1016/s0197-2456(97)00078-0 · Cited by 2,580
Calle, E. E., Heath Jr., C. W., Coates, R. J., Liff, J. M., Franceschi, S., Talamini, R., Chantarakul, N., Koetsawang, S., Rachawat, D., Morabia, A., et al. (1997) · The Lancet · doi:10.1016/s0140-6736(97)08233-0 · Cited by 2,450
Hormone Therapy To Prevent Disease and Prolong Life in Postmenopausal Women
Grady, D., Rubin, S. M., Petitti, D. B., Fox, C. S., Black, D. M., Ettinger, B. B., Ernster, V. L., & Cummings, S. R. (1992) · Annals of Internal Medicine · doi:10.7326/0003-4819-117-12-1016 · Cited by 2,329
Cardiovascular Disease Outcomes During 6.8 Years of Hormone Therapy
Grady, D. G., Herrington, D. M., Bittner, V., Blumenthal, R. S., Davidson, M., Hlatky, M. A., Hsia, J. A., Hulley, S. B., Herd, A. J., Khan, S. S., et al. (2002) · JAMA · doi:10.1001/jama.288.1.49 · Cited by 1,921
Stampfer, M. J., & Colditz, G. A. (1991) · Preventive Medicine · doi:10.1016/0091-7435(91)90006-p · Cited by 1,611
The use of estrogens and progestins and the risk of breast cancer in postmenopausal women.
Colditz, G. A., Hankinson, S. E., Hunter, D. J., Willett, W. C., Manson, J. E., Stampfer, M. J., Hennekens, C., Rosner, B., & Speizer, F. E. (1995) · New England Journal of Medicine · doi:10.1056/nejm199506153322401 · Cited by 1,487
Effects of Estrogen Replacement on the Progression of Coronary-Artery Atherosclerosis
Herrington, D. M., Reboussin, D. M., Brosnihan, K. B., Sharp, P. C., Shumaker, S. A., Snyder, T. E., Furberg, C. D., Kowalchuk, G. J., Stuckey, T. D., Rogers, W. J., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200008243430801 · Cited by 1,242
Grodstein, F., Manson, J. E., Colditz, G. A., Willett, W. C., Speizer, F. E., & Stampfer, M. J. (2000) · Annals of Internal Medicine · doi:10.7326/0003-4819-133-12-200012190-00008 · Cited by 1,063
Menopausal Estrogen and Estrogen-Progestin Replacement Therapy and Breast Cancer Risk
Schairer, C. (2000) · JAMA · doi:10.1001/jama.283.4.485 · Cited by 1,046
A Clinical Trial of Estrogen-Replacement Therapy after Ischemic Stroke
Viscoli, C. M., Brass, L. M., Kernan, W. N., Sarrel, P. M., Suissa, S., & Horwitz, R. I. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010534 · Cited by 919
Effect of Hormone Replacement Therapy on Breast Cancer Risk: Estrogen Versus Estrogen Plus Progestin
Ross, R. K. (2000) · Journal of the National Cancer Institute · doi:10.1093/jnci/92.4.328 · Cited by 877
Decreased Risk of Fractures of the Hip and Lower Forearm with Postmenopausal Use of Estrogen
Weiss, N. S., Ure, C. L., Ballard, J. H., Williams, A. R., & Daling, J. R. (1980) · New England Journal of Medicine · doi:10.1056/nejm198011203032102 · Cited by 774
Grady, D. G., WENGER, N. K., Herrington, D. M., Khan, S. S., Furberg, C. D., Hunninghake, D. B., Vittinghoff, E., & Hulley, S. B. (2000) · Annals of Internal Medicine · doi:10.7326/0003-4819-132-9-200005020-00002 · Cited by 712
Surveillance and ascertainment of cardiovascular events
Ives, D. G., Fitzpatrick, A. L., Bild, D. E., Psaty, B. M., Kuller, L. H., Crowley, P. M., Cruise, R. G., & Theroux, S. (1995) · Annals of Epidemiology · doi:10.1016/1047-2797(94)00093-9 · Cited by 688
A Meta-analysis of the Effect of Estrogen Replacement Therapy on the Risk of Breast Cancer
STEINBERG, K. K. (1991) · JAMA · doi:10.1001/jama.1991.03460150089030 · Cited by 648
Effects of Hormone Replacement Therapy on Endometrial Histology in Postmenopausal Women
Judd, H. L. (1996) · JAMA · doi:10.1001/jama.1996.03530290040035 · Cited by 605
Adams, M. R., Kaplan, J. R., Manuck, S. B., Koritnik, D. R., Parks, J. S., Wolfe, M. S., & Clarkson, T. B. (1990) · Arteriosclerosis An Official Journal of the American Heart Association Inc · doi:10.1161/01.atv.10.6.1051 · Cited by 603
Postmenopausal hormone therapy and the risk of colorectal cancer: a review and meta-analysis
Grodstein, F., Newcomb, P. A., & Stampfer, M. J. (1999) · The American Journal of Medicine · doi:10.1016/s0002-9343(99)00063-7 · Cited by 580
Hormone Replacement Therapy and Prevention of Nonvertebral Fractures
Torgerson, D. J., & Bell-Syer, S. E. (2001) · JAMA · doi:10.1001/jama.285.22.2891 · Cited by 528
Hormone Replacement Therapy and Cardiovascular Disease
Mosca, L. J., Collins, P. D., Herrington, D. M., Mendelsohn, M. E., Pasternak, R. C., Robertson, R. M., Schenck-Gustafsson, K. G., Smith, S. C., Taubert, K. A., & WENGER, N. K. (2001) · Circulation · doi:10.1161/hc2901.092200 · Cited by 437
Postmenopausal Hormone Therapy and Risk of Stroke
Simon, J. A., Hsia, J. A., Cauley, J. A., Richards, C., Harris, F., Fong, J., Barrett-Connor, E. L., & Hulley, S. B. (2001) · Circulation · doi:10.1161/01.cir.103.5.638 · Cited by 402
Effects of Estrogen and Estrogen–Progestin on Mammographic Parenchymal Density
Greendale, G. A., Reboussin, B. A., Sie, A., Singh, H. R., Olson, L. K., Gatewood, O. B., Bassett, L. W., Wasilauskas, C. H., Bush, T. L., Barrett-Connor, E. L., et al. (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-4_part_1-199902160-00003 · Cited by 400
Hulley, S. B., Furberg, C. D., & Barrett-Connor, E. L. (2002) · ACC Current Journal Review · doi:10.1016/s1062-1458(02)00920-0 · Cited by 338
Effect of Oral Postmenopausal Hormone Replacement on Progression of Atherosclerosis
Angerer, P., Störk, S., Kothny, W., Schmitt, P., & von Schacky, C. (2001) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.21.2.262 · Cited by 240
Effects of estrogen replacement on the progression of coronary artery atherosclerosis
Herrington, D. M., Beboussin, D. M., & Brosnihan, K. B. (2001) · ACC Current Journal Review · doi:10.1016/s1062-1458(00)00172-0 · Cited by 151
Alexander, K. P., Newby, L. K., Hellkamp, A. S., Harrington, R. A., Peterson, E. D., Kopecky, S., Langer, A., O’Gara, P. T., O’Connor, C. M., Daly, R. N., et al. (2001) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(01)01329-8 · Cited by 140
Effect of Hormone Replacement Therapy on Breast Cancer Risk: Estrogen Versus Estrogen Plus Progestin
Ross, R. K., Paganini‐Hill, A., Wan, P. C., & Pike, M. C. (2000) · Obstetrical & Gynecological Survey · doi:10.1097/00006254-200007000-00022 · Cited by 135
A Clinical Trial of Estrogen-Replacement Therapy After Ischemic Stroke
Viscoli, C. M., Brass, L. M., Kernan, W. N., Sarrel, P. M., Suissa, S., & Horwitz, R. I. (2002) · Obstetrical & Gynecological Survey · doi:10.1097/00006254-200203000-00019 · Cited by 125
Hulley, S. B., Furberg, C. D., Barrett-Connor, E. L., Cauley, J. A., Grady, D. G., Haskell, W. L., Knopp, R. H., Lowery, M. H., Satterfield, S., Schrott, H. G., et al. (2002) · Obstetrical & Gynecological Survey · doi:10.1097/00006254-200210000-00021 · Cited by 121
Reproductive factors, exogenous female hormones, and colorectal cancer by subsite
de Verdier, M. G., & London, S. J. (1992) · Cancer Causes & Control · doi:10.1007/bf00146889 · Cited by 113
Freedman, L. S., Anderson, G. L., Kipnis, V., Prentice, R. L., Wang, C. Y., Rossouw, J. E., Wittes, J. T., & DeMets, D. L. (1996) · Controlled Clinical Trials · doi:10.1016/s0197-2456(96)00016-5 · Cited by 102
Heckbert, S. R., Kaplan, R. C., Weiss, N. S., Psaty, B. M., Lin, D.-Y., Furberg, C. D., Starr, J. R., Anderson, G. D., & LaCroix, A. Z. (2001) · Archives of Internal Medicine · doi:10.1001/archinte.161.14.1709 · Cited by 97
Postmenopausal Hormone Use and Secondary Prevention of Coronary Events in the Nurses’ Health Study
Grodstein, F., Manson, J. E., & Stampfer, M. J. (2001) · Cited by 92
Hormone therapy to prevent disease and prolong life in postmenopausal women
Grady, D., Rubin, S., Petitti, D. B., Fox, C. S., Black, D., Ettinger, B. B., Ernster, V. L., & Cummings, S. R. (1993) · International Journal of Gynecology & Obstetrics · doi:10.1016/0020-7292(93)90679-q · Cited by 87
Effects of acute hormone therapy on recurrent ischemia in postmenopausal women with unstable angina
Schulman, S. P., Thiemann, D. R., Ouyang, P., CHANDRA, N. C., Schulman, D. S., Reís, S. E., Terrin, M. L., Forman, S. A., de Albuquerque, C. P., Bahr, R. D., et al. (2002) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(01)01724-7 · Cited by 74
The use of Estrogens and Progestins and the Risk of Breast Cancer in Postmenopausal Women
Colditz, G. A., Hankinson, S. E., Hunter, D. J., Willett, W. C., Manson, J. E., Stampfer, M. J., Hennekens, C. H., ROSNER, B. A., & Speizer, F. E. (1995) · Obstetrical & Gynecological Survey · doi:10.1097/00006254-199511000-00017 · Cited by 70
Estrogen replacement therapy: determinants of persistence with treatment
Pilon, D. (2001) · Obstetrics and Gynecology · doi:10.1016/s0029-7844(00)01104-2 · Cited by 56
Effect of estrone sulfate on postmenopausal bone loss
Genant, H. K., Baylink, D. J., Gallagher, J. C., Harris, S. T., Steiger, P., & Herber, M. (1991) · International Journal of Gynecology & Obstetrics · doi:10.1016/0020-7292(91)90313-t · Cited by 52
Effects of Estrogen Replacement on the Progression of Coronary-Artery Atherosclerosis
Herrington, D. M., Reboussin, D. M., Brosnihan, K. B., Sharp, P. C., Shumaker, S. A., Snyder, T. E., Furberg, C. D., Kowalchuk, G. J., Stuckey, T., Rogers, W. J., et al. (2001) · Obstetrical & Gynecological Survey · doi:10.1097/00006254-200101000-00020 · Cited by 52
Castellsagué, J., Perez‐Gutthann, S., & guez, L. A. G. A. R. (1998) · Drug Safety · doi:10.2165/00002018-199818020-00003 · Cited by 51
Postmenopausal hormone therapy and the risk of colorectal cancer: a review and meta-analysis
Grodstein, F., Newcomb, P. A., & Stampfer, M. J. (1999) · Climacteric · doi:10.3109/13697139909038076 · Cited by 39
Hormone Replacement Therapy and Cardiovascular Disease: The Case for a Randomized Controlled Trial
Vickers, M. R., Meade, T. W., & Wilkes, H. (2007) · Novartis Foundation symposium · doi:10.1002/9780470514757.ch9 · Cited by 29
Genazzani, A. R. (2002) · Circulation · doi:10.1161/01.cir.0000012248.01291.cf · Cited by 29
Simon, J. A., Hsia, J., & Cauley, J. A. (2001) · ACC Current Journal Review · doi:10.1016/s1062-1458(01)00300-2 · Cited by 25
91146870 A meta-analysis of the effect of estrogen replacement therapy on the risk of breast cancer
STEINBERG, K. K., Thacker, S. B., Smith, S. J., Stroup, D. F., Zack, M. M., Flanders, W. D., & Berkelman, R. L. (1991) · Maturitas · doi:10.1016/0378-5122(91)90165-m · Cited by 22
Mosca, L. J., Collins, P., Herrington, D. M., Mendelsohn, M. E., Pasternak, R. C., Robertson, R. M., Schenck-Gustafsson, K. G., Smith, S. C., Taubert, K. A., & Wenger, N. K. (2001) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · Cited by 19
Torgerson, D. J., & Bell-Syer, S. E. M. (2001) · White Rose Research Online (University of Leeds, The University of Sheffield, University of York) · Cited by 18
Grady, D. G., WENGER, N. K., Herrington, D. M., Khan, S. S., Furberg, C. D., Hunninghake, D. B., Vittinghoff, E., & for, S. H. (2000) · Obstetrical & Gynecological Survey · doi:10.1097/00006254-200011000-00021 · Cited by 16
Simon, J. A., Hsia, J. A., Cauley, J. A., Richards, C., Harris, F., Fong, J., Barrett-Connor, E. L., & Hulley, S. B. (2001) · Obstetrical & Gynecological Survey · doi:10.1097/00006254-200107000-00021 · Cited by 15
Alexander, K. P., Newby, L. K., & Hellkemp, A. S. (2001) · ACC Current Journal Review · doi:10.1016/s1062-1458(01)00455-x · Cited by 13
Magnusson (1999) · doi:10.1002/(sici)1097-0215(19990505)81:3
Flagged first, then by citations
Research works printed but not linked: 6
- [5]5. Rijpkema AH, van der Sanden AA, Ruijs AH. Ef- fects of postmenopausal estrogen-progesterone therapy on serum lipids and lipoproteins: a review. Ma- turitas. 1990;12:259-285.
- [18]18. Cox DR. Regression analysis and life tables. J R Stat Soc. 1972;34:187-220.
- [23]23. Writing Group for the PEPI Trial. Effects of estro- gen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. JAMA. 1995; 273:199-208.
- [25]25. Schulman SP, Thiemann DR, Ouyang P, et al. Ef- fects of acute hormone therapy on recurrent ische- mia in postmenopausal women with unstable an- gina. J Am Coll Cardiol. 2002;39:231-237.
- [29]29. Hodis HN, Mack WJ, Lobo RA, et al. Estrogen in the prevention of atherosclerosis: a randomized, double-blind controlled trial. Ann Intern Med. 2001; 135:939-953.
- [43]43. Writing Group for the PEPI Trial. Effects of hormone therapy on bone mineral density: results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA. 1996;275:1389- 1396.
Cited by
Sorted by citations
Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21660 · Cited by 108,699
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21492 · Cited by 84,109
Bray, F., Laversanne, M., Sung, H., Ferlay, J., Siegel, R. L., Soerjomataram, I., & Jemal, A. (2024) · CA: a cancer journal for clinicians · doi:10.3322/caac.21834 · Cited by 27,064
Chobanian, A. V. (2003) · JAMA · doi:10.1001/jama.289.19.2560 · Cited by 25,386
GRADE: an emerging consensus on rating quality of evidence and strength of recommendations
Guyatt, G. H., Oxman, A. D., Vist, G. E., Kunz, R., Falck-Ytter, Y., Alonso-Coello, P., & Schünemann, H. J. (2008) · BMJ · doi:10.1136/bmj.39489.470347.ad · Cited by 23,305
Metadata
- Authors
- Writing Group for the Women's Health Initiative Investigators
- Affiliations
- National Heart, Lung, and Blood Institute (US)
- Corresponding author
- Writing Group for the Women's Health Initiative Investigators
- Venue
- JAMA: The Journal of the American Medical Association
- Publisher
- American Medical Association (AMA)
- Published
- 2002-07-17
- Volume
- 288
- Issue
- 3
- Pages
- 321-333
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- 1538-3598
- OpenAlex
- W1593442063
- Cited by
- 15,889
- References
- 54
- Citations by year
- 2026: 283 · 2025: 348 · 2024: 342 · 2023: 365 · 2022: 459 · 2021: 465 · 2020: 452 · 2019: 453 · 2018: 455 · 2017: 452 · 2016: 486 · 2015: 572 · 2014: 546 · 2013: 688 · 2012: 713
- FWCI
- 647.30
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- JAMA (publishedVersion)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- eScholarship@UMassChan (submittedVersion)
- Funders
- Pfizer
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
- Health Sciences › Nursing › Nutrition and Dietetics › Phytoestrogen effects and research
- Keywords
- estrogen plus progestin, conjugated equine estrogens, medroxyprogesterone acetate, postmenopausal women, hormone replacement therapy, coronary artery disease, invasive breast cancer, stroke, pulmonary embolism, endometrial cancer, colorectal cancer, hip fracture, mortality, benefits and risks, Women's Health Initiative, early trial termination, primary prevention
- MeSH terms
- Aged, Breast Neoplasms, Coronary Disease, Estrogens, Conjugated (USP), Female, Humans, Middle Aged, Myocardial Infarction, Pulmonary Embolism, Risk, Thrombosis, Colorectal Neoplasms, Estrogen Replacement Therapy, Proportional Hazards Models, Survival Analysis, Endometrial Neoplasms, Treatment Outcome, Medroxyprogesterone Acetate, Postmenopause, Stroke, Clinical Trials Data Monitoring Committees, Progesterone Congeners, Fractures, Bone
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
